Relationship Between Hemoglobin Levels and Quality of Life During Radiation Therapy Plus Concomitant or Sequential Chemotherapy in Patients With Cancer and Anemia Treated With Epoetin Alfa

View More View Less
  • * From The Charles & Bernice Blitman Department of Radiation Oncology, Beth Israel Medical Center, New York, New York, and the Analysis Group/Economics, Boston, Massachusetts, and Université du Québec à Montréal, Montréal, Canada.

This study in patients with cancer and anemia, who were receiving chemoradiation and were treated with epoetin alfa, examined the relationship between hemoglobin level and quality of life (QOL), change in hemoglobin and change in QOL, and incremental (1 g/dL) increase in hemoglobin and related incremental improvement in QOL. Data from a multicenter, open-label, prospective study of once-weekly epoetin alfa therapy in anemic cancer patients receiving chemoradiation were used to retrospectively evaluate the relationship between hemoglobin changes and QOL changes via correlation and longitudinal analyses. A sample selection correction method was used to ensure unbiased results. QOL (energy, activity, overall QOL) was measured using the Linear Analog Scale Assessment. An incremental analysis determined the greatest incremental increase in QOL associated with a 1 g/dL increase in hemoglobin level. Of the 777 patients enrolled, 464 met chemotherapy and radiotherapy eligibility criteria. Of these, 359 (77%) underwent two QOL assessments and were eligible for analysis. A nonlinear and statistically significant positive correlation was found between hemoglobin levels and Linear Analog Scale Assessment QOL scores (r = 0.32 [energy], 0.33 [activity], and 0.29 [overall QOL]; P < .0001). An incremental analysis used regression methods to characterize the changes in hemoglobin levels and QOL scores. Hemoglobin change was found to be a statistically significant determinant of QOL changes (P < .05). The greatest incremental QOL gain associated with a 1-g/dL change in hemoglobin occurred around hemoglobin 12 g/dL (range, 11–13 g/dL). A direct relationship exists between hemoglobin increases and corresponding QOL increases. Maximal incremental gain in QOL occurred when hemoglobin was approximately 12 g/dL (range, 11–13 g/dL).

If the inline PDF is not rendering correctly, you can download the PDF file here.

Correspondence: Daniel Shasha, MD, The Charles & Bernice Blitman Department of Radiation Oncology, Beth Israel Medical Center, 10 Union Square East, New York, NY 10003. E-mail: dshasha@bethisraelny.org
  • 1

    Groopman JE, Itri LM. Chemotherapy-induced anemia in adults: Incidence and Treatment. J Natl Cancer Inst 1999;91:16161634.

  • 2

    Harrison LB, Shasha D, Homel P. Prevalence of anemia in cancer patients undergoing radiotherapy: prognostic significance and treatment. Oncology 2002;63(suppl 2):1118.

    • Search Google Scholar
    • Export Citation
  • 3

    Harrison L, Shasha D, Shiaova L. Prevalence of anemia in cancer patients undergoing radiation therapy. Semin Oncol 2001;28(suppl 8):5459.

  • 4

    Irvine D, Vincent L, Graydon JE. The prevalence and correlates of fatigue in patients receiving treatment with chemotherapy and radiotherapy: A comparison with the fatigue experienced by healthy individuals. Cancer Nurs 1994;17:367378.

    • Search Google Scholar
    • Export Citation
  • 5

    Vogelzang NJ, Breitbart W, Cella D. Patient, caregiver, and oncologist perceptions of cancer-related fatigue: Results of a tripart assessment survey. Semin Hematol 1997;3(suppl 2):412.

    • Search Google Scholar
    • Export Citation
  • 6

    Curt G, Breitbart W, Cella D. Impact of cancer-related fatigue on the lives of patients: New findings from The Fatigue Coalition. Oncologist 2000;5:353360.

    • Search Google Scholar
    • Export Citation
  • 7

    Stone P, Richards M, A'Hern R. Fatigue in patients with cancers of the breast or prostate undergoing radical radiotherapy. J Pain Symptom Manage 2001;22:10071015.

    • Search Google Scholar
    • Export Citation
  • 8

    Wang XS, Janjan NA, Guo H. Fatigue during preoperative chemoradiation for resectable rectal cancer. Cancer 2001;92(suppl 6):17251732.

  • 9

    Sobrero A, Puglisi F, Guglielmi A. Fatigue: A main component of anemia symptomatology. Semin Oncol 2001;28(suppl 8):1518.

  • 10

    Vigario G, Kurohara SS, George FW III. Association of hemoglobin levels before and during radiotherapy with prognosis in uterine cervix cancer. Radiology 1973;106:649652.

    • Search Google Scholar
    • Export Citation
  • 11

    Schreiner P, Siracká E, Siracký J. The effect of anemia on the radiotherapy results of the uterine cervix cancer. Neoplasma 1975;22:655660.

    • Search Google Scholar
    • Export Citation
  • 12

    Bush RS, Jenkin RDT, Allt WEC. Definitive evidence for hypoxic cells influencing cure in cancer therapy. Br J Cancer 1978;37(suppl III):302306.

    • Search Google Scholar
    • Export Citation
  • 13

    Girinski T, Pejovic-Lenfant MH, Bourhis J. Prognostic value of hemoglobin concentrations and blood transfusions in advanced carcinoma of the cervix treated by radiation therapy: Results of a retrospective study of 386 patients. Int J Radiat Oncol Biol Phys 1989;16:3742.

    • Search Google Scholar
    • Export Citation
  • 14

    Fyles A, Milosevic M, Wong R. Oxygenation predicts radiation response and survival in patients with cervix cancer. Radiother Oncol 1998;48:149156.

    • Search Google Scholar
    • Export Citation
  • 15

    Grogan M, Thomas GM, Melamed I. The importance of hemoglobin levels during radiotherapy for carcinoma of the cervix. Cancer 1999;86:15281536.

    • Search Google Scholar
    • Export Citation
  • 16

    Thomas G. The effect of hemoglobin level on radiotherapy outcomes: The Canadian experience. Semin Oncol 2001;28(suppl 8):6065.

  • 17

    Obermair A, Cheuk R, Horwood K. Impact of hemoglobin levels before and during concurrent chemoradiotherapy on the response of treatment in patients with cervical carcinoma: Preliminary results. Cancer 2001;92:903908.

    • Search Google Scholar
    • Export Citation
  • 18

    Dische S, Saunders MI, Warburton MF. Hemoglobin, radiation, morbidity and survival. Int J Radiat Oncol Biol Phys 1986;12:13351337.

  • 19

    Takigawa N, Segawa Y, Okahara M. Prognostic factors for patients with advanced non-small cell lung cancer: Univariate and multivariate analyses including recursive partitioning and amalgamation. Lung Cancer 1996;15:6777.

    • Search Google Scholar
    • Export Citation
  • 20

    Fein DA, Lee WR, Hanlon AL. Pretreatment hemoglobin level influenced local control and survival of T1-T2 squamous cell carcinomas of the glottic larynx. J Clin Oncol 1995;13:20772083.

    • Search Google Scholar
    • Export Citation
  • 21

    Glaser CM, Millesi W, Kornek GV. Impact of hemoglobin level and use of recombinant erythropoietin on efficacy of preoperative chemoradiation therapy for squamous cell carcinoma of the oral cavity and oropharynx. Int J Radiat Oncol Biol Phys 2001;50:705715.

    • Search Google Scholar
    • Export Citation
  • 22

    Constantinou E, Daly W, Fung C. Time-dose considerations in the treatment of anal cancer. Int J Radiat Oncol Biol Phys 1997;39:651657.

  • 23

    Dunphy EP, Petersen IA, Cox RS. The influence of initial hemoglobin and blood pressure levels on results of radiation therapy for carcinoma of the prostate. Int J Radiat Oncol Biol Phys 1989;16:11731184.

    • Search Google Scholar
    • Export Citation
  • 24

    Teicher BA. Physiologic mechanisms of therapeutic resistance: Blood flow and hypoxia. Hematol Oncol Clin North Am 1995;9:475506.

  • 25

    Harrison LB, Chadha M, Hill RJ. Impact of tumor hypoxia and anemia on radiation therapy outcomes. Oncologist 2002;7:492508.

  • 26

    Demetri G, Kris M, Wade J, for the Procrit Study Group. Quality-of-life benefit in chemotherapy patients treated with epoetin alfa is independent of disease response or tumor type: Results from a prospective community oncology study. J Clin Oncol 1998;16:34123425.

    • Search Google Scholar
    • Export Citation
  • 27

    Glaspy J, Bukowski R, Steinberg D, for the Procrit Study Group. Impact of therapy with epoetin alfa on clinical outcomes in patients with nonmyeloid malignancies during cancer therapy in community oncology practice. J Clin Oncol 1997;15:12181234.

    • Search Google Scholar
    • Export Citation
  • 28

    Littlewood TJ, Bajetta E, Nortier JWR, for the Epoetin Alfa Study Group. Effects of epoetin alfa on hematologic parameters and quality of life in cancer patients receiving nonplatinum chemotherapy: Results of a randomized, double-blind, placebo-controlled trial. J Clin Oncol 2001;19:28652874.

    • Search Google Scholar
    • Export Citation
  • 29

    Gabrilove J, Cleeland C, Livingston R. Clinical evaluation of once-weekly dosing of epoetin alfa in chemotherapy patients: Improvements in hemoglobin and quality of life are similar to three-times-weekly dosing. J Clin Oncol 2001;19:28752882.

    • Search Google Scholar
    • Export Citation
  • 30

    Crawford J, Cella D, Cleeland CS. Relationship between changes in hemoglobin level and quality of life during chemotherapy in anemic cancer patients receiving epoetin alfa therapy. Cancer 2002;95:888895.

    • Search Google Scholar
    • Export Citation
  • 31

    Churchill DN, Muirhead N, Goldstein M. Effect of recombinant human erythropoietin on hospitalization of hemodialysis patients. Clin Nephrol 1995;43:184188.

    • Search Google Scholar
    • Export Citation
  • 32

    Eschbach JW. The future of r-HuEPO. Nephrol Dial Transplant 1995;10(suppl 2):96109.

  • 33

    Iseki K, Nishime K, Uehara H. Increased risk of cardiovascular disease with erythropoietin in chronic dialysis patients. Nephron 1996;72:3036.

    • Search Google Scholar
    • Export Citation
  • 34

    Nissenson AR, Pickett JL, Theberge DC. Brain function is better in hemodialysis patients when hematocrit is normalized with erythropoietin (Abstr). J Am Soc Nephrol 1996;7:1459.

    • Search Google Scholar
    • Export Citation
  • 35

    Hillman RS, Finch CA. Erythropoietin regulation of erythropoiesis. In: Red Cell Manual, 7th ed. Philadelphia, PA: FA Davis Company; 1996:25.

    • Search Google Scholar
    • Export Citation
  • 36

    Dusenbery KE, McGuire W, Holt PJ. Erythropoietin increases hemoglobin during radiation therapy for cervical cancer. Int J Radiat Oncol Biol Phys 1994;29:10791084.

    • Search Google Scholar
    • Export Citation
  • 37

    Henke M, Guttenberger R, Barke A. Erythropoietin for patients undergoing radiology: A pilot study. Radiother Oncol 1999;50:185190.

  • 38

    Lavey RS, Dempsey WH. Erythropoietin increases hemoglobin in cancer patients during radiation therapy. Int J Radiat Oncol Biol Phys 1993;27:11471152.

    • Search Google Scholar
    • Export Citation
  • 39

    Sweeney PJ, Nicolae D, Ignacio L. Effect of subcutaneous recombinant human erythropoietin in cancer patients receiving radiotherapy: Final report of a randomized, open-labelled, phase II trial. Br J Cancer 1998;77:19962002.

    • Search Google Scholar
    • Export Citation
  • 40

    Shasha D, George MJ, Harrison LB. Once-weekly dosing of epoetin-α increases hemoglobin and improves quality of life in anemic cancer patients receiving radiation therapy either concomitantly or sequentially with chemotherapy. Cancer 2003:98:1072-1079.

    • Search Google Scholar
    • Export Citation
  • 41

    Heckman JJ. Sample selection bias as a specification error. Econometrica 1979;47:153161.

  • 42

    Spilker B. Quality of Life and Pharmacoeconomics in Clinical Trials, 2nd ed. Philadelphia, PA: Lippincott Williams & Wilkins; 1996.

  • 43

    Patrick DL, Gagnon DD, Zagari MJ. Assessing the clinical significance of health-related quality of life (HrQOL) improvements in anaemic cancer patients receiving epoetin alfa. Eur J Cancer 2003;39:335345.

    • Search Google Scholar
    • Export Citation
  • 44

    Shasha D, Harrison LB. Anemia treatment and the radiation oncologist: Optimizing patient outcomes. Oncology 2001;15:14861491.

  • 45

    Ludwig H, Birgegard G, Barrett-Lee P. Prevalence and management of anemia in patients (pts) with hematologic malignancies (HMs) and solid tumors (STs): Results from the European Cancer Anaemia Survey (ECAS) (Abstr). Blood 2002;100(11 pt 1):234a235a.

    • Search Google Scholar
    • Export Citation
  • 46

    Leyland-Jones B, on behalf of the BEST Investigators Study Group. Breast cancer trial with erythropoietin terminated unexpectedly. Lancet Oncol 2003;4:459460.

    • Search Google Scholar
    • Export Citation
  • 47

    Henke M, Laszig R, Rübe C. Erythropoietin to treat head and neck cancer patients with anaemia undergoing radiotherapy: Randomised, double-blind, placebo-controlled trial. Lancet 2003;362:12551260.

    • Search Google Scholar
    • Export Citation
  • 48

    Sabbatini P, Cella D, Chanan-Khan A. Cancer and treatment-related anemia. National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology, v.1.2004. Available at www.nccn.org. Accessed August 5, 2004.

    • Search Google Scholar
    • Export Citation
All Time Past Year Past 30 Days
Abstract Views 1 0 0
Full Text Views 134 33 2
PDF Downloads 136 68 10
EPUB Downloads 0 0 0